3 assets in Lung Sarcomatoid Carcinoma

Therapeutic assets addressing Lung Sarcomatoid Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Lung Sarcomatoid Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Ivocizumab Lung Sarcomatoid Carcinoma	Fudan University	P2	CCC (53)
Nivolumab Lung Sarcomatoid Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)